Download PDF
Semin Thromb Hemost 2002; 28(5): 483-490
DOI: 10.1055/s-2002-35289
Copyright © 2002 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA. Tel.: +1(212) 584-4662

Biological Relevance of Anti-Recombinant Hirudin Antibodies-Results from In Vitro and In Vivo Studies

Volker Liebe1 , Martina Brückmann1 , Karl-Georg Fischer2 , Karl Konstantin Haase1 , Martin Borggrefe1 , Günter Huhle1
  • 1Department of Cardiology, Faculty of Clinical Medicine Mannheim, University of Heidelberg, Mannheim, Germany
  • 2University Hospital Freiburg, Department of Medicine, Division of Nephrology and General Medicine, Freiburg, Germany
Further Information

Publication History

Publication Date:
06 November 2002 (online)

    Permissions and Reprints

ABSTRACT

This article provides an overview of the clinically relevant characteristics of antibodies directed toward recombinant (r) hirudin, with emphasis on the different ways in which these antibodies may influence pharmacokinetics and pharmacodynamics of r-hirudin. A high incidence of anti-hirudin antibody (AHAb) formation, mainly of the immunoglobulin G (IgG) subclass, was reported in up to 74% of patients treated with r-hirudin for more than 5 days. Like other drug-induced antibodies, AHAb may be responsible for accumulation or neutralization of the drug. Current clinical data support this assumption with reports on reduced metabolism, enhanced activity, and accumulation and neutralization of r-hirudin in the presence of AHAb. By examining AHAb developed in patients, we were able to demonstrate that AHAbs are capable of neutralizing r-hirudin in vitro. In addition, the anticoagulant activity of r-hirudin administered to Sprague-Dawley rats was almost completely abolished when a monoclonal mouse AHAb with known r-hirudin neutralizing capacity in vitro was injected intravenously. Because r-hirudin is mainly eliminated via the kidneys, formation of r-hirudin-AHAb complexes may, due to their size, result in accumulation of r-hirudin. We investigated filtration of r-hirudin incubated with monoclonal mouse AHAb by using high-flux hemodialyzers in a suitable in vitro model. Whereas sieving coefficients (SC) were high in the absence of AHAb, they were minimal (SC < 0.05) in the presence of AHAb. These findings may also be important when AHAb-positive patients treated with r-hirudin undergo hemofiltration procedures, which have recently been described as a rescue measure in case of r-hirudin overdosage. In vivo, the influence of a non-neutralizing monoclonal mouse AHAb on r-hirudin pharmacokinetics was examined in rats. Pharmacokinetic data compared with those of a control group without AHAb administration revealed that r-hirudin elimination half-life was significantly prolonged (59 ± 25 minutes versus 142 ± 25 minutes). This was accompanied by a decrease of total plasma clearance of r-hirudin. The volume of distribution of r-hirudin was significantly decreased (275 ± 112 mL/kg versus 35 ± 3 mL/kg), indicating that r-hirudin bound by AHAb is mainly distributed to the intravascular compartment. Taken together, both the half-life prolongation and the decrease of the volume of distribution contribute to r-hirudin accumulation and may explain respective findings in patients. In summary, two different effects of AHAbs seem to be clinically relevant: decreasing anticoagulant activity of r-hirudin by neutralization and accumulation of r-hirudin by reducing renal clearance. Formation of AHAbs has not yet been correlated with enhanced major bleeding complications. However, close monitoring of coagulation parameters is recommended in AHAb-positive patients during r-hirudin treatment.

KEYWORDS

Recombinant hirudin - anti-r-hirudin antibodies - neutralization - pharmacokinetics - hemofiltration

REFERENCES

  • 1 Dodt J, Mueller H P, Seemüller U, Chang J Y. The complete amino acid sequence of hirudin, a thrombin specific inhibitor.  FEBS Lett . 1984;  165 180-184
    CrossrefPubMedGoogle Scholar
  • 2 Markwardt F. The development of hirudin as an antithrombotic drug.  Thromb Res . 1994;  74 1-23
    CrossrefPubMedGoogle Scholar
  • 3 Märki W E, Grossenbacher H, Grütter M G. Recombinant hirudin: genetic engineering and structure analysis.  Semin Thromb Hemost . 1991;  17 88-93
    PubMedGoogle Scholar
  • 4 Esslinger H U, Haas S, Maurer R. Pharmocodynamic and safety results of PEG-hirudin in healthy volunteers.  Thromb Haemost . 1997;  77 911-919
    PubMedGoogle Scholar
  • 5 Wallis R B. Hirudin: from leeches to man.  Semin Thromb Hemost . 1996;  22 185-196
    PubMedGoogle Scholar
  • 6 Markwardt F, Nowak G, Stürzebecher J, Vogel G. Clinicopharmacological studies with recombinant hirudin.  Thromb Res . 1988;  52 393-400
    CrossrefPubMedGoogle Scholar
  • 7 Markwardt F, Fink G, Kaiser B. Pharmacological survey of recombinant hirudin.  Pharmazie . 1988;  43 202-207
    PubMedGoogle Scholar
  • 8 Eriksson B I, Ekman S, Kälebo P. Prevention of deep-vein thrombosis after total hip replacement: direct thrombin inhibition with recombinant hirudin, CGP 39393.  Lancet . 1996;  347 635-639
    CrossrefPubMedGoogle Scholar
  • 9 Eriksson B I, Wille-Jørgensen P, Kälebo P. A comparison of recombinant hirudin with a low-molecular-weight heparin to prevent thromboembolic complications after total hip replacement.  N Engl J Med . 1997;  337 1329-1335
    CrossrefPubMedGoogle Scholar
  • 10 Schiele F, Lindgaerde F, Eriksson H, for the International Multicentre Hirudin Study group. Subcutaneous recombinant hirudin (HBW 023) versus intravenous sodium heparin in treatment of established acute deep vein thrombosis of the legs: a multicentre prospective dose-ranging randomized trial.  Thromb Haemost . 1997;  77 834-838
    PubMedGoogle Scholar
  • 11 Zoldhelyi P, Webster M W, Fuster V. Recombinant hirudin in patients with chronic, stable coronary artery disease. Safety, half-life, and effect on coagulation parameters.  Circulation . 1993;  88 2015-2022
    PubMedGoogle Scholar
  • 12 Antmann E M, for the TIMI 9B investigators. Hirudin in acute myocardial infarction. Thrombolysis and thrombin Inhibition in Myocardial Infarction (TIMI) 9B trial.  Circulation . 1996;  94 911-921
    CrossrefPubMedGoogle Scholar
  • 13 GUSTO IIb investigators. The global use of strategies to open occluded coronary arteries: a comparison of recombinant hirudin with heparin for the treatment of acute coronary syndromes.  N Engl J Med . 1996;  335 775-782
    CrossrefPubMedGoogle Scholar
  • 14 Topol E J, Fuster V, Harrington R A. Recombinant hirudin for unstable angina pectoris: a multicenter randomized angiographic trial.  Circulation . 1994;  89 1557-1566
    PubMedGoogle Scholar
  • 15 Van den Bos A A, Deckers J W, Heyndrickx G J. Safety and efficacy of recombinant hirudin (CGP 39393) versus heparin in patients with stable angina undergoing coronary angioplasty.  Circulation . 1993;  88 2058-2066
    PubMedGoogle Scholar
  • 16 Antman E M. Hirudin in acute myocardial infarction. Thrombolysis and thrombin Inhibition in Myocardial Infarction (TIMI) 9B trial.  Circulation . 1996;  94 911-921
    CrossrefPubMedGoogle Scholar
  • 17 Greinacher A, Völpel H, Janssens U, for the HIT investigator group. Recombinant hirudin (lepirudin) provides safe and effective anticoagulation in patients with heparin-induced thrombocytopenia. A prospective study.  Circulation . 1999;  99 73-80
    CrossrefPubMedGoogle Scholar
  • 18 Greinacher A, Janssens U, Berg G. Lepirudin (recombinant hirudin) for parenteral anticoagulation in patients with heparin-induced thrombocytopenia.  Circulation . 1999;  199 587-593
    PubMedGoogle Scholar
  • 19 Harenberg J, Huhle G, Piazolo L, Wang L C, Heene D L. Anticoagulation in patients with heparin-induced thrombocytopenia type II.  Semin Thromb Hemost . 1997;  23 189-196
    PubMedGoogle Scholar
  • 20 Warkentin T E, Chong B H, Greinacher A. Heparin-induced thrombocytopenia: towards consensus.  Thromb Haemost . 1998;  79 1-7
    Article in Thieme ConnectPubMedGoogle Scholar
  • 21 Amiral J, Bridey F, Wolf M. Antibodies to macromolecular platelet factor 4-heparin complexes in heparin-induced thrombocytopenia: a study of 44 cases.  Thromb Haemost . 1995;  73 21-28
    PubMedGoogle Scholar
  • 22 Chong B H, Castaldi P A, Berndt M C. Heparin-induced thrombocytopenia: effects of rabbit IgG, and its Fab and Fc fragments on antibody-heparin-platelet interaction.  Thromb Res . 1989;  55 291-295
    CrossrefPubMedGoogle Scholar
  • 23 Cines D B, Tomaski A, Tannenbaum S. Immune endothelial-cell injury in heparin-associated thrombcytopenia.  N Engl J Med . 1987;  316 581-589
    CrossrefPubMedGoogle Scholar
  • 24 Warkentin T E, Kelton J G. A 14-year study of heparin-induced thrombocytopenia.  Am J Med . 1996;  101 502-507
    CrossrefPubMedGoogle Scholar
  • 25 Working P K. Potential effects of antibody induction by protein drugs. In: Ferraiolo BL, Mohler MA, Gloff CA, eds. Protein Pharmakokinetics and Metabolism New York: Plenum Press 1992: 73-92
    Google Scholar
  • 26 Markwardt F, Nowak G, Stürzebecher J. Clinical pharmacology of recombinant hirudin.  Haemostasis . 1991;  21(Suppl 1) 133-136
    PubMedGoogle Scholar
  • 27 Gygax D, Botta L, Ehrat M. Immunoassays in monitoring biotechnological drugs.  Ther Drug Monit . 1996;  18 405-409
    CrossrefPubMedGoogle Scholar
  • 28 Song X H, Huhle G, Wang L C, Hoffmann U, Harenberg J. Generation of anti-hirudin antibodies in heparin-induced thrombocytopenic patients treated with r-hirudin.  Circulation . 1999;  100 1528-1532
    CrossrefPubMedGoogle Scholar
  • 29 Huhle G, Hoffmann U, Song X. Immunologic response to recombinant hirudin in HIT type II patients during long-term treatment.  Br J Haematol . 1999;  106 195-201
    CrossrefPubMedGoogle Scholar
  • 30 Schlaeppi J M, Vekemans S, Rink H, Chang J Y. Preparation of monoclonal antibodies to hirudin and hirudin peptides.  Eur J Biochem . 1990;  188 463-470
    CrossrefPubMedGoogle Scholar
  • 31 Koch C, Whitechurch O, Cordier P, Roitsch C. Anti-hirudin monoclonal antibodies directed toward discontinuous epitopes of the hirudin amino-terminal and epitopes involving the carboxy-terminal hirudin amino acids.  Anal Biochem . 1993;  214 301-312
    CrossrefPubMedGoogle Scholar
  • 32 Huhle G, Liebe V, Hudek R, Heene D L. Anti-r-hirudin antibodies reveal clinical relevance through direct functional inactivation of r-hirudin or prolongation of r-hirudin's plasma halflife.  Thromb Haemost . 2001;  85 936-938
    PubMedGoogle Scholar
  • 33 Eichler P, Friesen H J, Lubenow N, Jäger B, Greinacher A. Antihirudin antibodies in patients with heparin-induced thrombocytopenia treated with lepirudin: incidence, effects on aPTT, and clinical relevance.  Blood . 2000;  96 2373-2378
    PubMedGoogle Scholar
  • 34 Liebe V, Piazolo L, Fischer K G. A monoclonal mouse anti r-hirudin antibody neutralizes r-hirudin in vivo-potential use as an antidote (Abst).  Ann Hematol . 2001;  80(Suppl I) A42
    PubMedGoogle Scholar
  • 35 Vanholder R C, Camez A A, Veys N M. Pharmacokinetics of recombinant hirudin in hemodialyzed end-stage renal failure patients.  Thromb Haemost . 1997;  77 650-655
    PubMedGoogle Scholar
  • 36 Koster A, Hansen R, Kruppe H. Recombinant hirudin as an alternative for anticoagulation during cardiopulmonary bypass in patients with heparin-induced thrombocytopenia type II: A 1-year experience in 57 patients.  J Cardiothorac Vasc Anesth . 2000;  14 243-248
    CrossrefPubMedGoogle Scholar
  • 37 Riess F C, Pötzsch B, Jäger K. Elimination von rekombinantem Hirudin aus der Blutzirkulation mittels Hämofiltration.  Hämostaseologie . 1997;  17 200-204
    PubMedGoogle Scholar
  • 38 Bauersachs R M, Lindhoff-Last E, Ehry A M. Treatment of hirudin overdosage in a patient with chronic renal failure.  Thromb Haemost . 1999;  81 323-324
    PubMedGoogle Scholar
      >